
浏览全部资源
扫码关注微信
1.江西中医药大学 附属医院,南昌 330006
2.江西中医药大学 附属医院 皮持衡名中医工作室,南昌 330006
宋卫国,主任中医师,副教授,从事中西医结合肾病临床与实验研究工作,Tel:0791-86362720,E-mail:swg7108@163.com
皮持衡,教授,主任医师,从事中医药治疗慢性肾脏病研究工作,Tel:0791-86362720,E-mail:pchn830@163.com
收稿日期:2020-12-30,
网络出版日期:2021-03-18,
纸质出版日期:2021-05-20
移动端阅览
宋卫国,彭璘,武雯雯等.基于Wnt/β-catenin调控EMT探讨益肾化瘀方对糖尿病肾病大鼠肾小球足细胞损伤的干预机制[J].中国实验方剂学杂志,2021,27(10):44-50.
SONG Wei-guo,PENG Lin,WU Wen-wen,et al.Intervention Mechanism of Yishen Huayu Prescription on Glomerular Podocyte Injury in Diabetic Nephropathy Rats Based on EMT Regulated by Wnt/β-catenin Pathway[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(10):44-50.
宋卫国,彭璘,武雯雯等.基于Wnt/β-catenin调控EMT探讨益肾化瘀方对糖尿病肾病大鼠肾小球足细胞损伤的干预机制[J].中国实验方剂学杂志,2021,27(10):44-50. DOI: 10.13422/j.cnki.syfjx.20210801.
SONG Wei-guo,PENG Lin,WU Wen-wen,et al.Intervention Mechanism of Yishen Huayu Prescription on Glomerular Podocyte Injury in Diabetic Nephropathy Rats Based on EMT Regulated by Wnt/β-catenin Pathway[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(10):44-50. DOI: 10.13422/j.cnki.syfjx.20210801.
目的
2
探讨基于Wnt/
β
-连环蛋白(
β
-catenin)调控上皮-间充质细胞转化(EMT)途径益肾化瘀方对糖尿病肾病(DN)肾小球足细胞损伤的干预机制。
方法
2
60只SD大鼠分为正常组,模型组,Wnt-C59组(Wnt/
β
-catenin通路抑制剂,0.03 g·kg
-1
),低、中、高剂量益肾化瘀方组(8,16,32 g·kg
-1
),12周后,比较各组一般体征变化及血肌酐(SCr),尿素氮(BUN),肾指数,尿蛋白量,血糖,肾脏病理改变,足细胞和肾小球基底膜损伤情况及足细胞损伤相关蛋白[去氧肾上腺素(nephrin),肾小球蛋白(synaptopodin)],Wnt/
β
-catenin通路相关蛋白(Wnt1,
β
-catenin),足细胞EMT相关蛋白[
α
-平滑肌肌动蛋白(
α
-SMA),E-钙黏蛋白(E-cadherin)]表达水平。
结果
2
与正常组比较,模型组肾组织出现明显病理改变,肾小球系膜基质弥漫性增厚,足突融合较为严重,SCr,BUN,肾指数,尿蛋白量,血糖及Wnt1,
β
-catenin,
α
-SMA表达水平明显升高(
P
<
0.05),nephrin,synaptopodin,E-cadherin表达水平明显下降(
P
<
0.05);与模型组比较,各干预组SCr,BUN,肾指数,尿蛋白量,血糖及Wnt1,
β
-catenin,
α
-SMA表达水平明显下降(
P
<
0.05),nephrin,synaptopodin,E-cadherin表达水平明显升高(
P
<
0.05);各干预组中,高剂量益肾化瘀方组对于上述指标的改善程度明显优于低、中剂量益肾化瘀方组(
P
<
0.05),与Wnt-C59组比较无显著差异。
结论
2
益肾化瘀方通过抑制Wnt/
β
-catenin通路阻止足细胞EMT,从而修复DN大鼠肾小球足细胞损伤。
Objective
2
To investigate the intervention mechanism of Yishen Huayu prescription on glomerular podocyte injury in diabetic nephropathy (DN) rats based on epithelialmesenchymal transition (EMT) regulated by Wnt/
β
-catenin pathway.
Method
2
The 60 SD rats were divided into control group, model group, Wnt-C59 group (0.03 g·kg
-1
Wnt/
β
-catenin pathway inhibitor), low-dose group (8 g·kg
-1
), medium-dose group (16 g·kg
-1
) and high-dose group (32 g·kg
-1
). After 12 weeks, various indexes , including general signs, serum creatinine (SCr), blood urea nitrogen (BUN), renal index, urinary protein, blood glucose, renal pathological changes, podocyte and expressions of glomerular basement membrane injury and podocyte injury related proteins [nephrin, synaptopodin], Wnt/
β
-catenin pathway related proteins (Wnt1,
β
-catenin), podocyte EMT related protein [
α
-smooth muscle actin (
α
-SMA), E-cadherin], were compared between groups.
Result
2
Compared with the control group, the renal tissue in the model group showed significant pathological changes, including diffuse thickening of glomerular mesangial matrix and severe foot process fusion, and a significant increase in SCr, BUN, renal indexes, urinary protein, blood glucose, Wnt1,
β
-catenin, and
α
-SMA expression levels (
P
<
0.05) as well as a significant decrease in nephrin, synaptopodin and E-cadherin expression levels(
P
<
0.05). Compared with model group, SCr, BUN, renal index, urinary protein, blood glucose, Wnt1,
β
-catenin, and
α
-SMA expression levels in each intervention group significantly decreased (
P
<
0.05), while the expression levels of nephrin, synaptopodin and E-cadherin significantly increased (
P
<
0.05). Among intervention groups, the improvement of above indexes in high-dose Yishen Huayu prescription group was the most obvious (
P
<
0.05), which was similar to the effect in Wnt-C59 group.
Conclusion
2
Yishen Huayu prescription prevents podocyte EMT by inhibiting Wnt/
β
-catenin pathway, thereby repairing glomerular podocyte injury in rats with diabetic nephropathy.
SHIN-ICHI A . Nephropathy [J]. Jpn J Clin Med , 2018 , 71 ( 11 ): 2010 - 2014 .
ZHONG F , CHEN H , XIE Y , et al . Protein S protects against podocyte injury in diabetic nephropathy [J]. J Am Soc Nephrol , 2018 , 29 ( 5 ): 1397 - 1410 .
胡维 , 熊丹 , 黄娟 . 补肾活血汤抑制糖尿病肾病引起的足细胞损伤及EMT发生机制研究 [J]. 天津中医药大学学报 , 2019 , 38 ( 3 ): 262 - 266 .
石明隽 , 田平平 , 刘忠强 , 等 . 控制血糖对糖尿病肾脏疾病大鼠肾脏组织Wnt4/ β -catenin信号通路及肾脏纤维化的影响 [J]. 中国糖尿病杂志 , 2019 , 27 ( 3 ): 66 - 71 .
张茹 , 许筠 , 翟晓丽 , 等 . 糖尿病肾病中医证型与实验室指标的相关性研究 [J]. 中国中西医结合肾病杂志 , 2018 , 19 ( 3 ): 205 - 207 .
吴学敏 , 赖杏荣 , 唐程 , 等 . 益肾化瘀方治疗2型糖尿病肾病(Ⅲ期)疗效及对结缔组织生长因子,肝细胞生长因子的影响 [J]. 中国中西医结合肾病杂志 , 2020 , 21 ( 7 ): 51 - 53 .
李惠 , 刘建林 , 牛聪 , 等 . 鸢尾黄素对大鼠糖尿病肾病的治疗作用 [J]. 广州中医药大学学报 , 2020 , 186 ( 6 ): 124 - 130 .
陈烨 , 严瑞 , 贾崇高 , 等 . 基于YKL-40和Wnt/ β -catenin通路探讨山茱萸颗粒对糖尿病肾病的保护作用 [J]. 中药材 , 2020 , 43 ( 4 ): 964 - 970
吕雁 , 张琳琪 , 王娇 . 益肾化瘀方对肾间质纤维化大鼠肾组织羟脯氨酸表达的影响 [J]. 中医学报 , 2020 , 35 ( 12 ): 140 - 146 .
QI C Y , SOMALI F A , ZHONG J Y , et al . Increased DAAM2,a new podocyte-associated protein,in diabetic nephropathy [J]. Nephrol Dial Transplant , 2021 , 3 ( 4 ): 3443 - 3446 .
芮丽 , 康建英 , 何清伟 , 等 . 赵怡蕊教授应用芪术胶囊干预糖尿病肾病的三羧酸循环机制初探 [J]. 中国中西医结合肾病杂志 , 2020 , 21 ( 4 ): 72 - 74 .
王丹 , 徐婧 , 李侠 , 等 . 芪地糖肾方辅助治疗糖尿病肾脏病Ⅲ期患者肾脏保护效果观察 [J]. 北京中医药 , 2020 , 39 ( 8 ): 105 - 108 .
张琳琪 , 李东洋 , 李俊惺 . 益肾化瘀方拮抗肾间质纤维化作用有效部位筛选 [J]. 中医学报 , 2017 , 32 ( 10 ): 156 - 160 .
张宏信 . 补肾化瘀法治疗糖尿病肾病56例临床研究 [J]. 亚太传统医药 , 2016 , 10 ( 6 ): 105 - 106 .
肖云 . 益肾化瘀方治疗糖尿病肾病疗效观察 [J]. 黑龙江医药科学 , 2016 , 39 ( 3 ): 121 - 122 .
CUNDY T , HOLDEN A , STALLWORTHY E . Early worsening of diabetic nephropathy in type 2 diabetes after rapid improvement in chronic severe hyperglycemia [J]. Diabetes Care , 2021 , 44 ( 3 ): 202646 - 202650 .
LIU J , CAI D , WANG Y , et al . SNHG15 knockdown inhibits diabetic nephropathy progression in pediatric patients by regulating the miR-141/ICAM-1 axis in vitro [J]. Biosci Rep , 2021 , 12 ( 9 ): 236 - 240 .
ZHANG H , YAN Y , HU Q , et al . LncRNA MALAT1/microRNA let-7f/KLF5 axis regulates podocyte injury in diabetic nephropathy [J]. Life Sci , 2021 , 266 ( 9 ): 118794 .
SHI M J , TIAN P P , LIU Z Q , et al . MicroRNA-27a targets Sfrp1 to induce renal fibrosis in diabetic nephropathy by activating Wnt/ β -catenin signalling [J]. Biosci Rep , 2020 , 40 ( 6 ): 23 - 30 .
XIANG X , CAI H D , SU S L , et al . Salvia miltiorrhiza protects against diabetic nephropathy through metabolome regulation and wnt/ β -catenin and TGF- β signaling inhibition [J]. Pharmacol Res , 2019 , 13 ( 9 ): 26 - 40 .
陆飞 . Wnt/ β -catenin信号通路在肾间质纤维化中的研究进展 [J]. 国际泌尿系统杂志 , 2019 , 39 ( 2 ): 374 - 376 .
闫喜惠 , 郭鹏 , 杨挺 , 等疮性肾炎患者尿液和肾组织Podocin、Nephrin蛋白表达及其与足细胞损伤的关系 [J]. 山东医药 , 2018 , 58 ( 46 ): 46 - 48 .
丁方睿 , 司南 , 边宝林 , 等 . 毛蕊花糖苷对嘌呤霉素肾病及足细胞损伤模型的疗效研究 [J]. 中华肾脏病杂志 , 2018 , 34 ( 1 ): 30 - 35 .
张娇 , 杨彩莲 , 张路 , 等 . 大鼠高糖记忆模型中足细胞向上皮间质细胞转化的转录组学分析 [J]. 解放军医学杂志 , 2020 , 45 ( 2 ): 64 - 72 .
石格 , 吴薇 , 万毅刚 , 等 . 低剂量雷公藤甲素抑制Wnt3 α / β -catenin信号通路活性改善高剂量D-葡萄糖诱导的足细胞转分化 [J]. 中国中药杂志 , 2018 , 43 ( 1 ): 139 - 146 .
WANG Y , LI H , SONG S P . β -Arrestin 1/2 aggravates podocyte apoptosis of diabetic nephropathy via Wnt/ β -catenin pathway [J]. Med Sci Monit , 2018 , 24 ( 4 ): 1724 - 1732 .
0
浏览量
17
下载量
8
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621